Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. Its stock price depends on sales of its core product, the Iluvien implant, and its ability to expand its use and sales geography.
Alimera Sciences is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of retinal diseases. We've categorized it under "Pharma: Eye," and the chart below shows how investors value companies in the highly specialized field of ophthalmology.
Alimera Sciences is a pharmaceutical company specializing in the development of drugs for the treatment of retinal diseases. As a component of the GURU.Markets index, it represents the ophthalmology sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
For Alimera Sciences, Inc., an ophthalmology company, daily volatility reflects its sensitivity to sales of its drugs. This metric is an indicator of demand for retinal disease treatments, serving as a basis for analysis.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. Ophthalmology is a highly specialized and competitive field. The chart below shows volatility in this sector, allowing you to assess how ALIM shares react to industry news.
Alimera Sciences is a pharmaceutical company specializing in the treatment of eye diseases. Its stock price depends on the success of its products in commercialization and regulatory approvals. These events create unique price movements that contribute to overall volatility.
For Alimera Sciences, year-over-year performance is a reflection of its niche ophthalmology products. Its 12-month market capitalization growth reflects sales of its ILUVIEN® and YUTIQ® implants for retinal diseases. Its valuation is a bet on its extended-release products finding their niche in this market.
Alimera Sciences, Inc. is a commercial pharmaceutical company focused on treating retinal diseases. This chart illustrates how its niche strategy, sales success of its key drug, and competitive environment influence its performance in the pharmaceutical sector.
Alimera Sciences, a pharmaceutical company specializing in retinal diseases, operates in a stable and growing market supported by an aging population. Its year-over-year market capitalization dynamics demonstrate how the commercial success of its core product influences its valuation, making it less dependent on economic cycles.
Alimera is a pharmaceutical company focused on retinal diseases. Its monthly performance reflects sales of its core product, the Iluvien eye implant. Quarterly revenue growth reports and expansion into new markets are the main drivers.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. Its main product is an implant for the treatment of diabetic macular edema. The chart below reflects sentiment in the ophthalmic pharmaceutical sector.
Alimera Sciences is a pharmaceutical company focused on retinal diseases. Its business is based on the treatment of chronic conditions often associated with aging. Its stock price is driven by the sales volume of its drugs and is not subject to general market cycles, reflecting stable demand in its medical niche.
Shares of Alimera Sciences, a company specializing in retinal diseases, are news-sensitive. Weekly price movements depend on sales data for its key drugs and clinical trial results. The chart below shows how short-term commercial and scientific events influence the valuation of this niche pharmaceutical company.
Alimera Sciences specializes in drugs for the treatment of retinal diseases. This is a niche but steadily growing market due to an aging population. The chart shows how this demographic support supports the company's stock price performance compared to other pharmaceutical market segments.
Alimera Sciences is a biopharmaceutical company. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by news about the progress of its drug candidates' clinical trials, not by the S&P 500.
Alimera Sciences' market capitalization reflects its business, built around a single product: an implant for the treatment of diabetic macular edema. The company's market capitalization is entirely dependent on sales of this niche ophthalmology drug. Its dynamics highlight the risks and opportunities associated with such a narrow specialization.
Alimera Sciences' market share in ophthalmology reflects its focus on treating retinal diseases. Its market share is driven by the success of its ocular implant, which provides sustained drug release for patients with diabetic macular edema, its key niche.
This chart shows the total market capitalization of pharmaceutical companies focused on retinal diseases. Alimera Sciences is one such player. The dynamics in the chart reflect how the market values long-acting niche drugs in this competitive field.
This chart visualizes the market value of the treatment of retinal diseases. Alimera Sciences' market capitalization is based on the valuation of its implant, which provides long-term treatment for diabetic edema. The line shows how this highly specialized product is building its significant market share in global ophthalmology.
This chart shows the scientific foundation of Alimera Sciences. Its line reflects the value of intellectual property for drugs used to treat retinal diseases. The trend reflects the commercial success of approved drugs, which are the company's main tangible asset.
Alimera Sciences' tangible assets include its R&D infrastructure and commercial network for marketing retinal disease treatments. The chart shows its share of this highly specialized pharmaceutical base.
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Alimera Sciences, as a development company, has a more streamlined model. Its value lies in the intellectual property of its eye treatments, not in the scale of its production.
Alimera Sciences specializes in treating retinal diseases. Its primary asset is an implant that delivers medication over several years and the commercial infrastructure for its distribution. The chart below illustrates the financial weight of this long-term therapy technology in ophthalmology.
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. Its market capitalization is based on its core product and its potential to treat millions of patients.
Alimera Sciences, Inc. is a pharmaceutical company specializing in the treatment of retinal diseases. Its value depends on the sales success of its drugs. This chart shows how the market values its commercial potential relative to its tangible assets.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. This chart shows how the market views their commercial product and its sales growth potential. The dynamics reflect commercial success and the competitive environment.
Alimera Sciences, a pharmaceutical company focused on retinal diseases, leverages its financial structure to market its ophthalmic implants. This chart shows how the company invests in its sales force and physician education programs to increase the penetration of its products in the ophthalmology market.
Alimera Sciences specializes in treating retinal diseases. This chart shows how its leverage reflects the investments required for marketing and sales of its core product, as well as for additional clinical trials to expand its application, which are key to growth in the ophthalmology market.
Allego is one of the leading operators of electric vehicle charging networks in Europe. Rapidly deploying such a network requires massive capital investment. This chart shows how aggressively the company is using debt to capture share in this strategically important and fast-growing market.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company finances the commercialization of its highly specialized drugs and manages its balance sheet.
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. Its primary product is an implant for the treatment of diabetic macular edema. This total debt chart helps assess how the company finances the marketing of its niche product and clinical trials to expand its use in ophthalmology.
This metric for Alimera Sciences, a pharmaceutical company focused on retinal diseases, measures the valuation of its commercial product. The P/E reflects the sales volume of its implant and its ability to grow its share in a highly specialized but stable market.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. Its flagship product is an implant that provides sustained drug delivery for the treatment of diabetic macular edema. This chart shows the average rating for the ophthalmic pharmaceutical sector, reflecting how the market values technologies that improve vision and quality of life for patients.
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. Its main product is an implant for the treatment of diabetic macular edema. This chart, reflecting overall sentiment, helps understand how investors value specialty pharmaceutical companies with a single key product.
Alimera Sciences is a pharmaceutical company specializing in drugs for the treatment of retinal diseases. This chart reflects future revenue expectations, which depend on successful sales of its key product and its expansion into new markets.
%20P%2FE%20Alimera%20Sciences&width=1500&height=450&colorIndex=35&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alimera-Sciences "Chart of the company's future (projected) P/E Alimera Sciences")
Alimera Sciences specializes in the treatment of retinal diseases, offering a long-acting drug. This chart compares its future profitability expectations with those of the pharmaceutical industry. It helps understand how the market views the commercial potential of its niche product and its ability to expand sales.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=36&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment "Future (projected) P/E graph of the market segment -")
Alimera Sciences specializes in medications for the treatment of retinal diseases. Demand for their products is driven by demographic trends (aging population) and healthcare reimbursement systems. The overall economic backdrop, visible in this graph, influences public and private budgets allocated to ophthalmological care.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole "Chart of the future (projected) P/E of the market as a whole")
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. Its financial performance depends on sales of its core product, an implant for the treatment of diabetic macular edema. This chart shows how marketing efforts and product adoption by ophthalmologists influence sales growth and profitability.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. This graph, showing overall sector profitability, reflects the demand for treatments for age-related and chronic diseases. The success of Alimera's long-term treatment products directly impacts patient quality of life and the financial performance of the entire ophthalmology industry.
Alimera Sciences specializes in medications for the treatment of retinal diseases. The company offers an implant that provides sustained drug release, reducing the number of injections. Its business is focused on a narrow but important niche in ophthalmology.
Alimera Sciences specializes in medications for the treatment of retinal diseases. Future profit projections depend on sales of its key products. Analysts are assessing demand from ophthalmologists and the competitive landscape in the eye health market.
%20profit%20of%20the%20company%20Alimera%20Sciences&width=1500&height=450&colorIndex=41&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alimera-Sciences "Graph of future (projected) profit of the company Alimera Sciences")
Alimera Sciences specializes in the development and commercialization of ophthalmic drugs for the treatment of retinal diseases. This chart shows revenue forecasts for the entire ophthalmic pharmaceutical sector. It helps understand how the company's niche strategy, focused on eye health, compares to overall pharmaceutical trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20&width=1500&height=450&colorIndex=42&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment "Graph of future (predicted) profits of companies in a market segment -")
Alimera Sciences specializes in the treatment of retinal diseases. Demand for its products is driven by medical necessity. However, general economic conditions, as reflected in this chart, can impact healthcare systems. During recessions, pricing pressure on pharmaceutical manufacturers can increase to control public healthcare spending.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole "Chart of future (predicted) profits of the market as a whole")
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. This chart, which compares its market capitalization with its drug sales, reflects its position in the highly specialized ophthalmology market. It shows how investors view its commercial efforts and the potential of its products for treating eye diseases.
Alimera Sciences is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of retinal diseases. Its lead product is designed to treat diabetic macular edema. This chart shows how investors value revenue in the ophthalmology sector, which helps understand how the market perceives the commercial potential of Alimera's products.
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. Its main product is an implant for the treatment of diabetic macular edema. This chart compares the revenue valuation of this niche pharmaceutical company with general market multiples.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. This chart shows how the market values the company based on projected future sales of its key drugs. It reflects expectations for growth in the ophthalmology market and the company's commercial efforts.
%20P%2FS%20Alimera%20Sciences&width=1500&height=450&colorIndex=47&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alimera-Sciences "The graph of the company's future (projected) P/S Alimera Sciences")
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. The chart shows the average estimated future sales in the ophthalmology sector. It helps understand how investors view the commercial success of its extended-release ILUVIEN implant and its prospects for further market adoption.
%20P%2FS%20market%20segment%20graph%20-%20&width=1500&height=450&colorIndex=48&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph "Future (projected) P/S market segment graph -")
Alimera Sciences (ALIM) is a pharmaceutical company specializing in the treatment of retinal diseases. Demand for their drugs is driven by medical needs and is not affected by economic cycles. This chart does not reflect their potential in ophthalmology and improving patients' vision.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole "Chart of the future (projected) P/S of the market as a whole")
This chart shows the revenue of Alimera Sciences, a pharmaceutical company specializing in retinal diseases. Revenue is generated almost entirely from sales of its ILUVIEN implant, which provides long-term treatment for diabetic macular edema. The growth reflects its adoption in ophthalmology practice.
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. Its revenue is generated by sales of ILUVIEN, a long-acting implant. The regional sales breakdown (US, Europe) demonstrates the company's success in expanding its presence in the global ophthalmology market.
Alimera Sciences, Inc. is a pharmaceutical company specializing in the treatment of retinal diseases. Demand for its drugs is driven by medical needs, not economic cycles. However, the overall economic situation, reflected in this chart, affects the solvency of the healthcare system and the insurance companies that cover the costs of expensive treatments.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. Sales of its implant depend on its acceptance by ophthalmologists. This chart shows analysts' expectations for ophthalmology drug market growth.
%20sales%20of%20the%20company%20Alimera%20Sciences&width=1500&height=450&colorIndex=53&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alimera-Sciences "Schedule of future (projected) sales of the company Alimera Sciences")
Alimera Sciences specializes in retinal diseases. This chart shows the outlook for the ophthalmic pharmaceutical sector. It reflects the aging population and the increasing prevalence of conditions such as diabetic macular edema, which creates strong demand for Alimera's products.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=54&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment "Schedule of future (projected) sales of companies in the market segment -")
The healthcare cost projections included in this chart are important for Alimera Sciences. The company specializes in treating retinal diseases, and demand for its medications depends on the stability of healthcare funding. Economic growth ensures this stability and patient affordability.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole "Schedule of future (predicted) sales of the market as a whole")
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. This chart shows the profitability of its key product—an implant that provides long-term therapy. Profitability depends on sales volume and acceptance of this treatment by ophthalmologists.
Alimera Sciences is a biopharmaceutical company specializing in the development of drugs for the treatment of retinal diseases. Profitability depends on sales of its eye implants. This chart shows the average profitability in the pharmaceutical industry. It helps assess how well Alimera is performing in the niche ophthalmology market.
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. Its main product is an implant for the treatment of diabetic macular edema. Demand depends on patient volume and insurance coverage. This curve, reflecting the overall economic situation, impacts healthcare budgets and patients' ability to afford treatment.
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. This chart reflects the size of its commercial and scientific teams. The dynamics illustrate the company's efforts to increase sales of its core product and expand its use into new markets, which requires investment in marketing and medical representatives.
Alimera Sciences specializes in the treatment of retinal diseases, offering an implant for the long-term treatment of diabetic macular edema. This chart shows the company's share of the total number of specialists in ophthalmic pharmaceuticals. This reflects its narrow specialization and deep expertise in the treatment of chronic eye diseases.
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. This chart, showing employment in ophthalmic pharmaceuticals, is important. The growing number of scientists and clinicians in this field demonstrates the high demand for new treatments for chronic eye diseases associated with an aging population.
Alimera Sciences specializes in medications for the treatment of retinal diseases. This overall employment rate reflects the healthcare system's ability to cover long-term and expensive treatments. A stable labor market ensures funding for insurance programs that cover the costs of Alimera's innovative therapies.
Alimera Sciences (ALIM) is a pharmaceutical company specializing in retinal diseases. Their main product is an implant for the treatment of diabetic macular edema. Their value is derived from their intellectual capital (product patent) and commercial infrastructure. This metric reflects the market valuation of their niche product.
%20of%20the%20company%20Alimera%20Sciences%20(ALIM)&width=1500&height=450&colorIndex=63&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alimera-Sciences-ALIM "Chart of market capitalization per employee (in thousands of dollars) of the company Alimera Sciences (ALIM)")
Alimera Sciences specializes in drugs for the treatment of retinal diseases. It is a niche pharmaceutical company. This metric helps assess how effectively the company operates in its niche. A high value may indicate high profitability of its products or a lean business model focused on marketing one or two drugs.
%20by%20market%20segment%20-%20&width=1500&height=450&colorIndex=64&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment "Market capitalization per employee (in thousands of dollars) by market segment -")
Alimera Sciences specializes in drugs for the treatment of retinal diseases. It is a niche pharmaceutical company. This chart shows how the market appreciates its focused approach, where a small team can successfully commercialize a product for a specific medical application, creating significant value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market "Market capitalization per employee (in thousands of dollars) for the overall market")
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. Their flagship product is the Iluvien implant for the treatment of diabetic macular edema. This chart shows how successfully their highly specialized commercial team is selling this niche, yet expensive, drug to ophthalmologists.
%20Chart%20Alimera%20Sciences%20(ALIM)&width=1500&height=450&colorIndex=66&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alimera-Sciences-ALIM "Company Profit Per Employee (in thousands of dollars) Chart Alimera Sciences (ALIM)")
Alimera Sciences is a pharmaceutical company specializing in retinal diseases. This chart reflects the commercial success of its products. For a company with one or more key drugs, high profit per employee indicates a strong market position, an effective sales team, and the demand for its therapies among doctors and patients.
%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=67&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment "Chart of profit per employee (in thousands of dollars) in the market segment -")
Alimera Sciences (ALIM) is a biopharmaceutical company specializing in the treatment of retinal diseases. Their products are drug-delivering implants. They are a niche biotech with commercial products. This chart shows how a company with an approved but very niche drug generates profits. Employee efficiency depends on the high price of the drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Alimera Sciences specializes in drugs for the treatment of retinal diseases. This chart demonstrates the commercial success of their products, such as Iluvien. The high revenue per employee in the biopharma industry is a sign of the demand for their highly specialized treatments.
&width=1500&height=450&colorIndex=69&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alimera-Sciences-ALIM "Sales chart per company employee Alimera Sciences (ALIM)")
Alimera Sciences is a pharmaceutical company specializing in the treatment of retinal diseases. Their products (Iluvien, Yutiq) are sustained-release ocular implants. This chart shows how productive their commercial team is in selling these niche, high-tech drugs to ophthalmologists.
Ivanhoe Electric (IE) is a mineral exploration and development company focused on metals critical to electrification (copper, gold, silver). They also use their "Typhoon" technology for geophysical exploration. During the exploration phase, the company generates no sales revenue. This schedule will be zero. The entire staff (geologists and engineers) is dedicated to creating future value through the discovery and evaluation of deposits.
Alimera Sciences (ALIM) sells a drug for treating eye diseases. It's a niche company struggling for growth. This chart shows the number of short positions. Bears may doubt that sales of this drug will ever grow significantly.
&width=1500&height=450&colorIndex=72&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alimera-Sciences-ALIM "Short Shares Chart for the Company Alimera Sciences (ALIM)")
Alimera Sciences (ALIM) specializes in drugs for treating retinal diseases (such as the ILUVIEN implant). The chart below shows the overall short position in the ophthalmology biotech sector. It reflects the degree of investor skepticism about the commercial potential of highly specialized drugs.
Alimera (ALIM) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like ALIM in favor of safer assets.
This chart for Alimera is an indicator of demand for their Iluvien eye implant. The company sells the implant for the treatment of diabetic retinal edema. "Overbought" levels (above 70) arise from strong sales growth reports. Competition from injections (Eylea) and slow physician adoption of the implant limit growth, leading to "oversold" levels (below 30).
&width=1500&height=450&colorIndex=75&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alimera-Sciences-ALIM "RSI 14 indicator chart for the company's stock Alimera Sciences (ALIM)")
Alimera is a "biotech" company, a "hunter" for *eyes*. Their "thing" is *implants* (Iluvien, Yutiq), which *slowly* (over years) *release* a drug to treat *retinal diseases*. The "Pharma eyes" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It helps us understand: is ALIM's growth a "niche" or is *the entire* biotech "overheated"?
Alimera Sciences (ALIM) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Alimera Sciences specializes in the treatment of retinal diseases, offering extended-release implants (Iluvien, Yutiq). This chart shows the average analyst estimate for the commercial success of these niche drugs. Their forecast reflects expectations for sales growth and competition in ophthalmology.
&width=1500&height=450&colorIndex=78&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALIM-Alimera-Sciences "A chart showing analyst consensus forecasts for the expected stock price. ALIM (Alimera Sciences)")
Alimera (ALIM) is a laser-focused company in ophthalmology. The company specializes in treating retinal diseases with its extended-release implant (Iluvien). This chart measures the gap between the current price and the consensus target price. It shows the sales potential analysts see for this niche ophthalmology drug.
&width=1500&height=450&colorIndex=79&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALIM-Alimera-Sciences "A chart showing the difference between the consensus forecast and the actual stock price. ALIM (Alimera Sciences)")
Alimera specializes in retinal treatments, specifically implants (Iluvien) for the treatment of diabetic edema. It's a niche but competitive market. This chart shows analysts' overall expectations for the entire ophthalmic pharmaceutical sector. It reflects whether experts believe demand for eye treatments will grow (due to an aging population) or anticipate pricing pressure.
Alimera Sciences (ALIM) is a pharmaceutical company focused on the retina. Their signature product is mini-implants (Iluvien), which are inserted into the eye and deliver medication for months, saving the sight of diabetics. This chart shows the general sentiment of experts. It reflects the extent to which analysts believe in the stability of the healthcare system and its willingness to pay for expensive, niche procedures.
Alimera is a pharmaceutical company focused on the back of the eye. Their signature product is ILUVIEN, a micro-implant (not drops) that has been delivering medication for diabetic retinal edema for years. This chart summarizes their commercialization history, reflecting their (slow) sales growth and their ability to convince doctors of this niche.
Alimera Sciences specializes in complex retinal diseases, offering implants (Iluvien) that deliver medication over several years. This is a niche ophthalmology practice. This chart compares their composite index to the sector, showing how their eye-focused business performs compared to competitors.
Alimera Sciences is a pharmaceutical company specializing in ophthalmology (diabetic macular edema). Its key product is Iluvien. This chart, which reflects the market average, provides a macro backdrop. It helps assess how ALIM, a niche drug, fares against the backdrop of overall economic trends.
